Oxford, 15 June 2017 – OMass Technologies (“OMass”), a biotechnology company using structural mass spectrometry to drive drug discovery, today announced that it has secured an Innovate UK Grant of £461,000.
The funds have been awarded to develop a sample delivery platform for analysing intact receptor-drug complexes using mass spectrometry (MS). The project is being run in collaboration with the laboratory of OMass founder, Prof Dame Carol Robinson at the University of Oxford. The new platform holds promise of being able to automate native MS screening efforts, using picomole amounts of material for each acquisition. A recent publication in Angewandte Chemie from Prof. Robinson’s research group demonstrate a range of potential applications for the technology.
OMass specialises in applying state-of-the-art mass spectrometry platforms to characterising intact protein assemblies. By providing both access to technology and expertise through collaborations with world-leading pharmaceutical companies, the company is focussed on studying some of the most challenging protein targets in drug discovery.
JW Communications +44 (0)7818430877
Julia Wilson firstname.lastname@example.org
Notes for Editors:
About OMass Therapeutics
OMass Therapeutics is a private biopharmaceutical company, focused on structural mass spectrometry to discover novel medicines. The company uses its suite of proprietary technologies based on high-resolution mass spectrometry to study intact protein assemblies. The technology enables detection of drug leads that not only bind to the target complex, but also exert a functional effect through modulating complex formation. These methods are being applied to drug discovery for a variety of complex targets, including membrane receptors, addressing severe unmet medical needs. OMass is backed by Syncona Ltd and Oxford Sciences Innovation. For further information please visit the Company’s website at: www.omass.com.
July 28, 2020
May 15, 2020
February 25, 2020